ARS Pharmaceuticals, Inc.SPRYNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +3043.40% | +1471.62% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +2046.60% | +1142.84% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.52% | +1.90% | +1.63% | +1.58% | +1.83% |
| Weighted Average Shares Diluted Growth | +1.52% | +1.90% | +1.63% | +1.58% | +1.83% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +52.21% | +1052.45% | +1562.46% | +4712.18% | +2841.97% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +988.39% |
| Asset Growth | -12.45% | +50.59% | +43.82% | +41.23% | +71.32% |
| Book Value per Share Growth | -16.57% | +9.21% | +0.64% | -12.04% | -27.85% |
| Debt Growth | -68.81% | -84.67% | -66.36% | +938.13% | +1401.96% |
| R&D Expense Growth | +47.34% | -11.08% | -43.60% | -41.49% | -37.80% |
| SG&A Expenses Growth | +0.00% | +0.00% | +0.00% | +507.25% | +287.69% |